MBF Therapeutics is a veterinary oncology company developing innovative small molecule drugs and immunotherapies for dogs and cats with cancer. Our product development portfolio includes targeted treatments that specifically disrupt tumor cell metabolism and stimulate potent, systemic immune responses that destroy tumors without affecting normal, healthy cells and organs.
Effective cancer treatment is one of the most significant unmet needs in veterinary medicine today. As pets live longer, they are increasingly susceptible to a variety of age-related chronic conditions, including heart disease, kidney disease, obesity and cancer. It has been estimated that nearly half of all pets over the age of 10 will develop cancer.
Despite recent advances, including therapeutics adapted from human medicine, the primary cancer treatment options for dogs and cats are surgery, radiation, and chemotherapy. These palliative measures offer only a nominal extension of life, often with a significant degradation of overall quality of life for pets and their owners.
MBFT’s state-of-the-art oncology products are intended to meet the growing demand for effective cancer therapies that address not only symptoms but also treat the underlying disease to bring patients into long-lasting remission that will extend and maintain good quality of life.